iTeos Therapeutics and Calidi Biotherapeutics Head-To-Head Review
| ITOS Stock | USD 7.83 0.23 2.85% |
Slightly above 62% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Iteos |
Calidi Biotherapeutics and iTeos Therapeutics are both small-cap medical companies, but which is the better stock We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Institutional and Insider Ownership 12.5 percent of Calidi
Read at thelincolnianonline.com
 |
Iteos Therapeutics Fundamental Analysis
We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Iteos Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Iteos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.
Peers
Iteos Therapeutics Related Equities
| BPMC | Blueprint Medicines | 5.39 | ||||
| ERAS | Erasca | 3.00 | ||||
| KYMR | Kymera Therapeutics | 2.56 | ||||
| DAWN | Day One | 1.64 | ||||
| RVMD | Revolution Medicines | 1.12 | ||||
| TCRX | Tscan Therapeutics | 1.01 | ||||
| APLS | Apellis Pharmaceuticals | 0.73 | ||||
| ABOS | Acumen Pharmaceuticals | 1.08 | ||||
| TERN | Terns Pharmaceuticals | 1.40 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.04 | ||||
| MLTX | MoonLake Immunotherapeuti | 2.98 | ||||
| GLUE | Monte Rosa | 5.22 | ||||
| SANA | Sana Biotechnology | 5.71 | ||||
| DSGN | Design Therapeutics | 6.18 | ||||
| ANNX | Annexon | 6.65 |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.